Amrubicin as second-line treatment for small-cell lung cancer:a Meta-analysis

VernacularTitle:氨柔比星用于小细胞肺癌二线治疗的荟萃分析
Author: Haichao JIN ¹ ; Fangkai XING ; Tao CHEN ; Wenling LV
Author Information

1. 烟台71571部队
Keywords: amrubicin; small-cell lung cancer; chemotherapy
From: Journal of Pharmaceutical Practice 2017;35(1):82-86
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer (SCLC ) . Methods PubMed ,Embase ,the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC .A Meta-analysis was performed over the published clinical trials .The efficacy and safety of amrubicin were evaluated based on overall survival (OS) ,progression-free survival (PFS) ,overall response rate (ORR) and toxicity .Results Our anal-ysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group [RR 1 .72 ,95% CI (1 .39 , 2.14) ,P=0 .000] ,the OS ,PFS and toxicity were no-inferior to the control group(P=0 .405 ,P=0.456) .Conclusion Am-rubicin can be considered as a good second-line treatment for relapsed SCLC .